Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway

Src homolog and collagen homolog binding protein 1 (SHCBP1) binds to the SH2 domain of SHC‐transforming protein 1 (SHC1) and is involved in midbody organization and cytokinesis completion. SHCBP1 has been reported to be a cancer driver gene, promoting cancer progression. However, the functional role and underlying mechanism of SHCBP1 in regulating lung adenocarcinoma (LUAD) cell proliferation and migration are incompletely understood. Here, we discovered that SHCBP1 is overexpressed in LUAD tissues and is associated with a poor prognosis. SHCBP1 knockdown inhibited LUAD cell proliferation and migration by arresting the cell cycle and preventing epithelial–mesenchymal transition (EMT) via decreasing cyclin‐dependent kinase 1 (CDK1) expression. Mechanistically, CDK1 overexpression reversed SHCBP1 knockdown‐induced inhibition of proliferation and migration, confirming CDK1 as a key downstream target of SHCBP1. In addition, we proposed that rucaparib may be a small‐molecule inhibitor of SHCBP1 and validated both in vitro and in vivo that rucaparib inhibits cell proliferation and migration via suppression of the SHCBP1/CDK1 pathway in LUAD. Our study elucidates a newly identified role of SHCBP1 in promoting cell proliferation and migration in LUAD, and suggests rucaparib as a potential inhibitor for LUAD treatment. Src homolog and collagen homolog binding protein 1 (SHCBP1) is overexpressed and associated with a poor prognosis in lung adenocarcinoma (LUAD). SHCBP1 knockdown inhibited LUAD cell proliferation and migration by decreasing cyclin‐dependent kinase 1 (CDK1) expression. Overexpression of CDK1 reversed SHCBP1 knockdown‐inhibited cell proliferation and migration. Meanwhile, we demonstrated that rucaparib could inhibit A549 cell proliferation, migration and tumor growth in vitro and in vivo via suppression of the SHCBP1/CDK1 pathway, suggesting that rucaparib is a potential inhibitor of SHCBP1 in LUAD.